Treatment Choices: Rheumatoid Arthritis Case Study

Dr. Christopher Parker, a rheumatologist with The Austin Diagnostic Clinic in Austin, Texas, reviews the following case of a women with rheumatoid arthritis interested in receiving a JAK inhibitor.

Case: Rheumatoid arthritis (RA) active disease in an adult female patient with inadequate response to methotrexate.

Initial Presentation and Treatment:

• A 53-year-old woman was diagnosed with RA approximately 7 years ago.
  • Confirmed by anti-cyclic citrullinated peptide testing
• Following diagnosis, she received methotrexate at 10 mg/week, which was escalated to 25 mg/week over time
  • She received modified-release prednisone 5 mg/day in the evenings
  • She has not received a biological DMARD

Subsequent Treatment and Follow-up:

• On a scale of 0 to 100 mm by visual analog scale, PhGA is 64, the PtGA is 62, and pain is 63.
• DAS28-CRP is 5.8, DAS28-ESR is 6.5, and hs-CRP is 20 mg/L
• Lab measures are normal for neutrophil, lymphocyte, hemoglobin, and liver enzyme counts
• The patient went on to receive upadacitinib at 15 mg/day.